“Unless the FDA changes course, consumers and taxpayers will soon shoulder an additional $4 billion a year in drug costs. Worse, the FDA’s plan to allow different labels on brand name drugs and their generic competitors could confuse patients and their doctors—threatening patient safety. Representative Steve Israel and Representative Tim Bishop should be commended for speaking out in their recent letter to the FDA. They … Continue reading Without Changes, Proposed Labeling Rule Would Drive Up Costs for Consumers, Taxpayers